600196.SH
复星医药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 22.79
−3.27%Year over year
Reported trailing growth
- Revenue
- +4.9%
- EBITDA
- —
- EBIT
- +14.5%
- EPS
- +19.3%
- Free cash flow
- +159.5%
- Operating cash flow
- +15.0%
Forward estimates
Based on analyst estimates
- Revenue
- -0.8%
- EBITDA
- -4.1%
- EPS
- -23.7%
Three-year CAGR
- Revenue
- -1.8%
- EBITDA
- +7.6%
- EBIT
- +3.9%
- Net income
- -3.3%
- EPS
- -3.9%
- Free cash flow
- +1045.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026